PSNI announces option to pay retention fees in instalments


Share post:

The Pharmaceutical Society NI (PSNI) has announced plans to facilitate the payment of retention fees by quarterly instalments, beginning June 2024.

Last year, discontent with the burden of the cost of professional retention fees was communicated directly with the Pharmacists Defence Association (PDA) National Officer for Northern Ireland, Una O’Farrell.

The association quickly took action on the comments received and issued a survey to members who are PSNI registrants, seeking their views as a collective.

The survey revealed that 97 per cent of members responding to the survey felt the fees were too high. 80 per cent of members surveyed would opt to pay in instalments if this option were available to them.

On average, the fees accounted for 23 per cent of a pharmacist’s take-home pay for one month.

The PDA presented these findings to the newly appointed chief executive and president of PSNI, who collaborated to find ways to alleviate this burden on pharmacists.

The association said: “The PDA is pleased to note that as an action of that meeting, the PSNI has listened to what pharmacists have said. This option to spread the cost brings the profession into line with peers, and the PDA is proud to have played a part in making this change on pharmacists behalf.

The PDA encourages all members to bring issues like this forward to representatives, networks and national officers, to inform future campaigning on pharmacists behalf.”


Please enter your comment!
Please enter your name here

Current Issue June 2023

Related articles

MHRA grants authorisation for LEO Pharma’s Adtralza 2 mL pen solution

The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the marketing authorisation of Adtralza, a dermatological solution...

Grundon launches maiden UK-wide inhaler recycling programme

Grundon Waste Management has introduced what it claims to be the UK's first verified nationwide inhaler return and...

‘Record fine imposed on hydrocortisone manufacturers for dominant position abuse and 10,000% price increase’

The Competition Appeal Tribunal (CAT) has upheld the Competition and Markets Authority’s (CMA) findings against two pharmaceutical manufacturers...

Vision Report: Legal reforms, adequate funding imperative for success of community pharmacy

Achieving the community pharmacy vision necessitates legal adjustments and additional funding beyond recent boosts, the pharmacy vision document...